Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | GALK1 | P51570 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28918823 | 0.86 | ALDH1A1 (0.46) | ALDH1A1NPSR1SOAT1THRBGLO1 | |
| SCHEMBL2117165 | 0.86 | ALDH1A1 (0.46) | ALDH1A1NPSR1SOAT1THRBGLO1 | |
| SCHEMBL243193 | 0.86 | ALDH1A1 (0.46) | ALDH1A1NPSR1SOAT1THRBGLO1 | |
| SCHEMBL27838163 | 0.81 | NPSR1 (0.52) | ALDH1A1NPSR1THRBGLO1HSD17B10 | |
| SCHEMBL20530243 | 0.81 | HCAR2 (0.48) | ALDH1A1NPSR1THRBLMNAKMT2A | |
| SCHEMBL29374091 | 0.81 | HCAR2 (0.48) | ALDH1A1NPSR1THRBLMNAKMT2A | |
| SCHEMBL1321694 | 0.81 | NPSR1 (0.65) | ALDH1A1NPSR1SOAT1GLO1HSD17B10 | |
| SCHEMBL5612231 | 0.81 | NPSR1 (0.65) | ALDH1A1NPSR1SOAT1GLO1HSD17B10 | |
| SCHEMBL5667523 | 0.81 | NPSR1 (0.65) | ALDH1A1NPSR1SOAT1GLO1HSD17B10 | |
| Ethane SCHEMBL28049845 | 0.79 | NPSR1 (0.63) | ALDH1A1NPSR1GLO1HSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2012500285-A | — | — | 2012-01-05 | — | — | JP | claimed |
| EP-2334378-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XenoPort, Inc. (US) | 2011-06-22 | — | — | EP | claimed |
| US-20260007627-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | BIOGEN MA INC (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4215191-A1 | COMPOSITION COMPRISING A FUMARATE FOR USE IN A METHOD OF TREATING MULTIPLE SCLEROSIS | Biogen MA Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20220072117-A1 | Dimethyl Fumarate and Vaccination Regimens | BIOGEN MA INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-11246850-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210315854-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | BIOGEN MA INC. | 2021-10-14 | — | — | US | disclosed |
| US-11129806-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20210228701-A1 | Dimethyl Fumarate and Vaccination Regimens | BIOGEN MA INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-11007166-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-11007167-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20150209318-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE | BIOGEN MA INC. | 2015-07-30 | — | — | US | disclosed |
| EP-2811994-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE | Biogen Idec MA Inc. (US) | 2014-12-17 | — | — | EP | disclosed |
| WO-2014190056-A2 | PRODRUGS AND DRUGS | BIOGEN IDEC MA INC. (US) | 2014-11-27 | — | — | WO | disclosed |
| US-20130295169-A1 | Pharmaceutical Compositions Containing Dimethyl Fumarate | BIOGEN MA INC. | 2013-11-07 | — | — | US | disclosed |
| US-20130216615-A1 | Pharmaceutical Compositions Containing Dimethyl Fumarate | BIOGEN IDEC MA INC. | 2013-08-22 | — | — | US | disclosed |
| WO-2013119677-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE | BIOGEN IDEC MA INC. (US) | 2013-08-15 | — | — | WO | disclosed |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8148414-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| EP-2334378-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XenoPort, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11129806-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | ALDH1A1 3424/4885NPSR1 3629/4885SOAT1 1552/4885 |
| US-11007167-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | ALDH1A1 3424/4885NPSR1 3629/4885SOAT1 1552/4885 |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | FH, MGMT, BHMT2 | ALDH1A1 1970/4885NPSR1 3954/4885SOAT1 1778/4885 |
| US-20260007627-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | FH, SLC6A6, SLC6A13 | ALDH1A1 3705/4885NPSR1 3649/4885SOAT1 2658/4885 |
| US-20150209318-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE | FH, FAH, MGMT | ALDH1A1 2678/4885NPSR1 4514/4885SOAT1 1773/4885 |
| US-11007166-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | ALDH1A1 3424/4885NPSR1 3629/4885SOAT1 1552/4885 |
| US-11246850-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | ALDH1A1 3424/4885NPSR1 3629/4885SOAT1 1552/4885 |
| US-20210228701-A1 | Dimethyl Fumarate and Vaccination Regimens | FH, HLA-DRB1, SDHB | ALDH1A1 3688/4885NPSR1 4559/4885SOAT1 1474/4885 |
| US-20210315854-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | FAH, FH, PML | ALDH1A1 3424/4885NPSR1 3629/4885SOAT1 1552/4885 |
| US-20130216615-A1 | Pharmaceutical Compositions Containing Dimethyl Fumarate | FH, FAH, MGMT | ALDH1A1 2678/4885NPSR1 4514/4885SOAT1 1773/4885 |
| US-20220072117-A1 | Dimethyl Fumarate and Vaccination Regimens | FH, HLA-DRB1, SDHB | ALDH1A1 3688/4885NPSR1 4559/4885SOAT1 1474/4885 |
| US-20130295169-A1 | Pharmaceutical Compositions Containing Dimethyl Fumarate | FH, FAH, MGMT | ALDH1A1 2678/4885NPSR1 4514/4885SOAT1 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.